Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests(1694 views) Andreotti G, Citro V, De Crescenzo A, Orlando P, Cammisa M, Correra A, Cubellis MV
Orphanet Journal Of Rare Diseases (ISSN: 1750-1172), 2011 Oct 17; 6: 66-66.
Keywords: 1-Deoxynojirimycin Pharmacology Therapeutic Use, Animals, Base Sequence, Cos Cells Metabolism, Catalytic Domain, Cercopithecus Aethiops, Fabry Disease Drug Therapy Enzymology Genetics, Female, Humans, Models, Molecular, Molecular Chaperones Pharmacology Therapeutic Use, Molecular Sequence Data, Muramidase, Mutagenesis, Site-Directed, Mutation, Missense, Predictive Value Of Tests, Alpha-Galactosidase Drug Effects Genetics Metabolism, Alpha Galactosidase, Migalastat, 1 Deoxynojirimycin, Lysozyme, Animal Cell, Article, Computer Model, Drug Mechanism, Gene Mutation, Genotype, In Vitro Study, Nonhuman, Western Blotting, Cell Strain Cos1, Chemical Structure, Enzyme Active Site, Evaluation, Missense Mutation, Molecular Genetics, Nucleotide Sequence, Site Directed Mutagenesis,
Affiliations: *** IBB - CNR ***
Istituto di Chimica Biomolecolare - CNR, Pozzuoli, Italy. giuseppina.andreotti@icb.cnr.it
Institute of Genetics and Biophysics A. Buzzati Traverso, CNR, Naples, Italy
Dipartimento di Scienze Ambientali, Seconda Università di Napoli, Caserta, Italy
Institute of Protein Biochemistry, CNR, Napoli, Italy
Dipartimento di Biologia Strutturale e Funzionale, Università Federico II, Napoli, Italy
Istituto di Biostrutture e Bioimmagini, CNR, Napoli, Italy
References: Germain, D.P., Fabry disease (2010) Orphanet Journal of Rare Diseases, 5, p. 30. , 10.1186/1750-1172-5-30 2109218
Ishii, S., Chang, H.-H., Kawasaki, K., Yasuda, K., Wu, H.-L., Garman, S.C., Fan, J.-Q., Mutant α-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: Biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin (2007) Biochemical Journal, 406 (2), pp. 285-295. , DOI 10.1042/BJ20070479
Whybra, C., Kampmann, C., Willers, I., Davies, J., Winchester, B., Kriegsmann, J., Bruhl, K., Beck, M., Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes (2001) Journal of Inherited Metabolic Disease, 24 (7), pp. 715-724. , DOI 10.1023/A:1012993305223
Poorthuis, B.J.H.M., Wevers, R.A., Kleijer, W.J., Groener, J.E.M., De Jong, J.G.N., Van Weely, S., Niezen-Koning, K.E., Van Diggelen, O.P., The frequency of lysosomal storage diseases in The Netherlands (1999) Human Genetics, 105 (1-2), pp. 151-156. , DOI 10.1007/s004399900075
Meikle, P.J., Hopwood, J.J., Clague, A.E., Carey, W.F., Prevalence of lysosomal storage disorders (1999) Journal of the American Medical Association, 281 (3), pp. 249-254. , DOI 10.1001/jama.281.3.249
Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., Sakuraba, H., Ponzone, A., Desnick, R.J., High incidence of later-onset Fabry disease revealed by newborn screening (2006) American Journal of Human Genetics, 79 (1), pp. 31-40. , DOI 10.1086/504601
Hgmd, (2011) Public Version:HGMD, , http://www.hgmd.cf.ac.uk/ac/index.php
Schaefer, E., Mehta, A., Gal, A., Genotype and phenotype in Fabry disease: Analysis of the Fabry Outcome Survey (2005) Acta Paediatr Suppl, 94 (447), pp. 87-92. , discussion 79. 16214772
Schiffmann, R., Brady, R.O., (2006) Development of Enzyme Replacement Therapy for Fabry Disease
Fan, J.-Q., Ishii, S., Asano, N., Suzuki, Y., Accelerated transport and maturation of lysosomal α-galactosidase A in fabry lymphoblasts by an enzyme inhibitor (1999) Nature Medicine, 5 (1), pp. 112-115. , DOI 10.1038/4801
Khanna, R., Benjamin, E.R., Pellegrino, L., Schilling, A., Rigat, B.A., Soska, R., Nafar, H., Lun, Y., The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase (2010) Febs J, 277 (7), pp. 1618-1638. , 10.1111/j.1742-4658.2010.07588.x 20148966
Germain, D.P., Fan, J.Q., Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: In vitro and preclinical studies (2009) International Journal of Clinical Pharmacology and Therapeutics, 47 (SUPPL 1), pp. 19111-117. , 20040321
Filoni, C., Caciotti, A., Carraresi, L., Cavicchi, C., Parini, R., Antuzzi, D., Zampetti, A., Garman, S.C., Functional studies of new GLA gene mutations leading to conformational Fabry disease (2010) Biochimica et Biophysica Acta, 1802 (2), pp. 247-252. , 19941952
Benjamin, E.R., Flanagan, J.J., Schilling, A., Chang, H.H., Agarwal, L., Katz, E., Wu, X., Desnick, R.J., The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines (2009) J Inherit Metab Dis, 32 (3), pp. 424-440. , 10.1007/s10545-009-1077-0 19387866
Shin, S.H., Kluepfel-Stahl, S., Cooney, A.M., Kaneski, C.R., Quirk, J.M., Schiffmann, R., Brady, R.O., Murray, G.J., Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone (2008) Pharmacogenet Genomics, 18 (9), pp. 773-780. , 10.1097/FPC.0b013e32830500f4 18698230
Shimotori, M., Maruyama, H., Nakamura, G., Suyama, T., Sakamoto, F., Itoh, M., Miyabayashi, S., Wataya-Kaneda, M., Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone (2008) Hum Mutat, 29 (2), p. 331. , 18205205
Park, J.Y., Kim, G.H., Kim, S.S., Ko, J.M., Lee, J.J., Yoo, H.W., Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease (2009) Experimental & Molecular Medicine, 41 (1), pp. 1-7. , 10.3858/emm.2009.41.1.001 22013587
Andreotti, G., Guarracino, M.R., Cammisa, M., Correra, A., Cubellis, M.V., Prediction of the responsiveness to pharmacological chaperones: Lysosomal human alpha-galactosidase, a case of study (2010) Orphanet Journal of Rare Diseases, Orphanet Journal of Rare Diseases, 5, p. 36
Cheng, J., Randall, A., Baldi, P., Prediction of protein stability changes for single-site mutations using support vector machines (2006) Proteins: Structure, Function and Genetics, 62 (4), pp. 1125-1132. , DOI 10.1002/prot.20810
Worth, C.L., Bickerton, G.R., Schreyer, A., Forman, J.R., Cheng, T.M., Lee, S., Gong, S., Blundell, T.L., A structural bioinformatics approach to the analysis of nonsynonymous single nucleotide polymorphisms (nsSNPs) and their relation to disease (2007) J Bioinform Comput Biol, 5 (6), pp. 1297-1318. , 10.1142/S0219720007003120 18172930
Topham, C.M., Srinivasan, N., Blundell, T.L., Prediction of the stability of protein mutants based on structural environment-dependent amino acid substitution and propensity tables (1997) Protein Engineering, 10 (1), pp. 7-21
Ashton-Prolla, P., Tong, B., Shabbeer, J., Astrin, K.H., Eng, C.M., Desnick, R.J., Fabry disease: Twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes (2000) J Investig Med, 48 (4), pp. 227-235. , 10916280
Ashley, G.A., Shabbeer, J., Yasuda, M., Eng, C.M., Desnick, R.J., Fabry disease: Twenty novel α-galactosidase a mutations causing the classical phenotype (2001) Journal of Human Genetics, 46 (4), pp. 192-196. , DOI 10.1007/s100380170088
Calado, J., Soto, K., Clemente, C., Correia, P., Rueff, J., Gene symbol: GLA, Disease:Fabry disease (2004) Human Genetics, 115, p. 347
Yang, C.-C., Lai, L.-W., Whitehair, O., Hwu, W.-L., Chiang, S.-C., Lien, Y.-H.H., Two novel mutations in the α-galactosidase A gene in Chinese patients with Fabry disease (2003) Clinical Genetics, 63 (3), pp. 205-209. , DOI 10.1034/j.1399-0004.2003.00050.x
Shabbeer, J., Robinson, M., Desnick, R.J., Detection of α-galactosidase A mutations causing fabry disease by denaturing high performance liquid chromatography (2005) Human Mutation, 25 (3), pp. 299-305. , DOI 10.1002/humu.20144
Topaloglu, A.K., Ashley, G.A., Tong, B., Shabbeer, J., Astrin, K.H., Eng, C.M., Desnick, R.J., Twenty novel mutations in the α-galactosidase a gene causing fabry disease (1999) Molecular Medicine, 5 (12), pp. 806-811
Dobrovolny, R., Dvorakova, L., Ledvinova, J., Magage, S., Bultas, J., Lubanda, J.C., Elleder, M., Hrebicek, M., Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the α-galactosidase a gene in the Czech and Slovak population (2005) Journal of Molecular Medicine, 83 (8), pp. 647-654. , DOI 10.1007/s00109-005-0656-2
Lieberman, R.L., D'Aquino, J.A., Ringe, D., Petsko, G.A., Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability (2009) Biochemistry, 48 (22), pp. 4816-4827. , 10.1021/bi9002265 19374450
Cubellis, M.V., Caillez, F., Blundell, T.L., Lovell, S.C., Properties of polyproline II, a secondary structure element implicated in protein-protein interactions (2005) Proteins: Structure, Function and Genetics, 58 (4), pp. 880-892. , DOI 10.1002/prot.20327
Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W., Lipman, D.J., Gapped BLAST and PSI-BLAST: A new generation of protein database search programs (1997) Nucleic Acids Research, 25 (17), pp. 3389-3402. , DOI 10.1093/nar/25.17.3389
Ciftci, K., Levy, R.J., Enhanced plasmid DNA transfection with lysosomotropic agents in cultured fibroblasts (2001) International Journal of Pharmaceutics, 218 (1-2), pp. 81-92. , DOI 10.1016/S0378-5173(01)00623-8, PII S0378517301006238
Smith, R.E., Lovell, S.C., Burke, D.F., Montalvao, R.W., Blundell, T.L., Andante: Reducing side-chain rotamer search space during comparative modeling using environment-specific substitution probabilities (2007) Bioinformatics, 23 (9), pp. 1099-1105. , DOI 10.1093/bioinformatics/btm073
Mizuguchi, K., Deane, C.M., Blundell, T.L., Johnson, M.S., Overington, J.P., JOY: Protein sequence-structure representation and analysis (1998) Bioinformatics, 14 (7), pp. 617-623. , DOI 10.1093/bioinformatics/14.7.617
Connolly, M.L., Solvent-accessible surfaces of proteins and nucleic acids (1983) Science, 221 (4612), pp. 709-713. , 10.1126/science.6879170 6879170
Tsukimura, T., Chiba, Y., Ohno, K., Saito, S., Tajima, Y., Sakuraba, H., Molecular mechanism for stabilization of a mutant alpha-galactosidase A involving M51I amino acid substitution by imino sugars (2011) Molecular Genetics and Metabolism, 103 (1), pp. 26-32. , 10.1016/j.ymgme.2011.01.013 21353612
Ishii, S., Suzuki, Y., Fan, J.-Q., Role of Ser-65 in the activity of α-galactosidase A: Characterization of a point mutation (S65T) detected in a patient with Fabry disease (2000) Archives of Biochemistry and Biophysics, 377 (2), pp. 228-233. , DOI 10.1006/abbi.2000.1743
Yam, G.H., Bosshard, N., Zuber, C., Steinmann, B., Roth, J., Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants (2006) American Journal of Physiology, 290 (4), pp. 31076-1082. , 16531566
Ferri, L., Guido, C., La Marca, G., Malvagia, S., Cavicchi, C., Fiumara, A., Barone, R., Feliciani, C., Fabry disease: Polymorphic haplotypes and a novel missense mutation in the GLA gene (2011) Clinical Genetics
Wu, X., Katz, E., Valle, C.D., Mascioli, K., Flanagan, J., Castelli, J.P., Schiffmann, R., Valenzano, K.J., A pharmacogenetic approach to identify mutant forms of alpha-galactosidase a that respond to a pharmacological chaperone for Fabry disease (2011) Hum Mutat, 32 (8), pp. 965-77. , 10.1002/humu.21530 21598360
Germain, D. P., Fabry disease (2010) Orphanet Journal of Rare Diseases, 5, p. 30. , 10. 1186/1750-1172-5-30 2109218
Poorthuis, B. J. H. M., Wevers, R. A., Kleijer, W. J., Groener, J. E. M., De Jong, J. G. N., Van Weely, S., Niezen-Koning, K. E., Van Diggelen, O. P., The frequency of lysosomal storage diseases in The Netherlands (1999) Human Genetics, 105 (1-2), pp. 151-156. , DOI 10. 1007/s004399900075
Meikle, P. J., Hopwood, J. J., Clague, A. E., Carey, W. F., Prevalence of lysosomal storage disorders (1999) Journal of the American Medical Association, 281 (3), pp. 249-254. , DOI 10. 1001/jama. 281. 3. 249
Fan, J. -Q., Ishii, S., Asano, N., Suzuki, Y., Accelerated transport and maturation of lysosomal -galactosidase A in fabry lymphoblasts by an enzyme inhibitor (1999) Nature Medicine, 5 (1), pp. 112-115. , DOI 10. 1038/4801
Germain, D. P., Fan, J. Q., Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: In vitro and preclinical studies (2009) International Journal of Clinical Pharmacology and Therapeutics, 47 (SUPPL 1), pp. 19111-117. , 20040321
Benjamin, E. R., Flanagan, J. J., Schilling, A., Chang, H. H., Agarwal, L., Katz, E., Wu, X., Desnick, R. J., The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines (2009) J Inherit Metab Dis, 32 (3), pp. 424-440. , 10. 1007/s10545-009-1077-0 19387866
Shin, S. H., Kluepfel-Stahl, S., Cooney, A. M., Kaneski, C. R., Quirk, J. M., Schiffmann, R., Brady, R. O., Murray, G. J., Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone (2008) Pharmacogenet Genomics, 18 (9), pp. 773-780. , 10. 1097/FPC. 0b013e32830500f4 18698230
Park, J. Y., Kim, G. H., Kim, S. S., Ko, J. M., Lee, J. J., Yoo, H. W., Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease (2009) Experimental & Molecular Medicine, 41 (1), pp. 1-7. , 10. 3858/emm. 2009. 41. 1. 001 22013587
Worth, C. L., Bickerton, G. R., Schreyer, A., Forman, J. R., Cheng, T. M., Lee, S., Gong, S., Blundell, T. L., A structural bioinformatics approach to the analysis of nonsynonymous single nucleotide polymorphisms (nsSNPs) and their relation to disease (2007) J Bioinform Comput Biol, 5 (6), pp. 1297-1318. , 10. 1142/S0219720007003120 18172930
Topham, C. M., Srinivasan, N., Blundell, T. L., Prediction of the stability of protein mutants based on structural environment-dependent amino acid substitution and propensity tables (1997) Protein Engineering, 10 (1), pp. 7-21
Ashley, G. A., Shabbeer, J., Yasuda, M., Eng, C. M., Desnick, R. J., Fabry disease: Twenty novel -galactosidase a mutations causing the classical phenotype (2001) Journal of Human Genetics, 46 (4), pp. 192-196. , DOI 10. 1007/s100380170088
Yang, C. -C., Lai, L. -W., Whitehair, O., Hwu, W. -L., Chiang, S. -C., Lien, Y. -H. H., Two novel mutations in the -galactosidase A gene in Chinese patients with Fabry disease (2003) Clinical Genetics, 63 (3), pp. 205-209. , DOI 10. 1034/j. 1399-0004. 2003. 00050. x
Topaloglu, A. K., Ashley, G. A., Tong, B., Shabbeer, J., Astrin, K. H., Eng, C. M., Desnick, R. J., Twenty novel mutations in the -galactosidase a gene causing fabry disease (1999) Molecular Medicine, 5 (12), pp. 806-811
Lieberman, R. L., D'Aquino, J. A., Ringe, D., Petsko, G. A., Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability (2009) Biochemistry, 48 (22), pp. 4816-4827. , 10. 1021/bi9002265 19374450
Cubellis, M. V., Caillez, F., Blundell, T. L., Lovell, S. C., Properties of polyproline II, a secondary structure element implicated in protein-protein interactions (2005) Proteins: Structure, Function and Genetics, 58 (4), pp. 880-892. , DOI 10. 1002/prot. 20327
Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., Lipman, D. J., Gapped BLAST and PSI-BLAST: A new generation of protein database search programs (1997) Nucleic Acids Research, 25 (17), pp. 3389-3402. , DOI 10. 1093/nar/25. 17. 3389
Smith, R. E., Lovell, S. C., Burke, D. F., Montalvao, R. W., Blundell, T. L., Andante: Reducing side-chain rotamer search space during comparative modeling using environment-specific substitution probabilities (2007) Bioinformatics, 23 (9), pp. 1099-1105. , DOI 10. 1093/bioinformatics/btm073
Connolly, M. L., Solvent-accessible surfaces of proteins and nucleic acids (1983) Science, 221 (4612), pp. 709-713. , 10. 1126/science. 6879170 6879170
Yam, G. H., Bosshard, N., Zuber, C., Steinmann, B., Roth, J., Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants (2006) American Journal of Physiology, 290 (4), pp. 31076-1082. , 16531566
Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests
Background: Fabry disease is a rare disorder caused by a large variety of mutations in the gene encoding lysosomal alpha-galactosidase. Many of these mutations are unique to individual families. Fabry disease can be treated with enzyme replacement therapy, but a promising novel strategy relies on small molecules, so called "pharmacological chaperones", which can be administered orally. Unfortunately only 42% of genotypes respond to pharmacological chaperones. Results: A procedure to predict which genotypes responsive to pharmacological chaperones in Fabry disease has been recently proposed. The method uses a position-specific substitution matrix to score the mutations. Using this method, we have screened public databases for predictable responsive cases and selected nine representative mutations as yet untested with pharmacological chaperones. Mutant lysosomal alpha galactosidases were produced by site directed mutagenesis and expressed in mammalian cells. Seven out of nine mutations responded to pharmacological chaperones. Nineteen other mutations that were tested with pharmacological chaperones, but were not included in the training of the predictive method, were gathered from literature and analyzed in silico. In this set all five mutations predicted to be positive were responsive to pharmacological chaperones, bringing the percentage of responsive mutations among those predicted to be positive and not used to train the classifier to 86% (12/14). This figure differs significantly from the percentage of responsive cases observed among all the Fabry mutants tested so far. Conclusions: In this paper we provide experimental support to an "in silico" method designed to predict missense mutations in the gene encoding lysosomal alpha galactosidase responsive to pharmacological chaperones. We demonstrated that responsive mutations can be predicted with a low percentage of false positive cases. Most of the mutations tested to validate the method were described in the literature as associated to classic or mild classic phenotype. The analysis can provide a guideline for the therapy with pharmacological chaperones supported by experimental results obtained in vitro. We are aware that our results were obtained in vitro and cannot be translated straightforwardly into benefit for patients, but need to be validated by clinical trials.
Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests